Northwestern Mutual Wealth Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-10
Closed -$11 3818
2025
Q2
$11 Hold
10
﹤0.01% 3626
2025
Q1
$13 Hold
10
﹤0.01% 3616
2024
Q4
$23 Sell
10
-1
-9% -$2 ﹤0.01% 3540
2024
Q3
$37 Hold
11
﹤0.01% 3531
2024
Q2
$55 Buy
+11
New +$82 ﹤0.01% 3418

Other funds holding BCLI

Northwestern Mutual Wealth Management's BCLI Position: Q3 2025 in Review

Northwestern Mutual Wealth Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 10 shares — an estimated $11 sold.

Northwestern Mutual Wealth Management first reported a position in BCLI in Q2 2024 and held it in 5 quarters. The position peaked at $55 in Q2 2024. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

  • Northwestern Mutual Wealth Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
  • Northwestern Mutual Wealth Management sold 10 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $11.
  • Northwestern Mutual Wealth Management first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2024 and held it in 5 quarters.
  • Northwestern Mutual Wealth Management's BRAINSTORM CELL THERAPUTC position peaked at $55 in Q2 2024.
  • 5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on Northwestern Mutual Wealth Management's 13F filing for Q3 2025, filed 14 Nov 2025.